nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

26.01.2021 | short review

Pain and palliative care treatment in daily practice

verfasst von: Dr. Markus Köstenberger, Univ.-Prof. Dr. Rudolf Likar, MSc

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Summary

In addition to other distressing symptoms, palliative patients often suffer from very severe pain. For this reason, a precise pain diagnosis is necessary in order to be able to initiate the necessary therapeutic measures. Pain therapy includes the medications specified in the World Health Organization (WHO) analgesic ladder as well as various supportive measures.

Vorheriger Artikel Clinical characteristics and treatment of delirium in palliative care settings

Nächster Artikel ASCO 2020: highlights in breast cancer

Smith AK, et al. The epidemiology of pain during the last 2 years of life. Ann Intern Med. 2010;153:563–9.CrossRef

Gill TM, Han L, Leo-Summers L, Gahbauer EA, All-ore HG. Distressing symptoms, disability, and hospice services at the end of life: prospective cohort study. J Am Geriatr Soc. 2018;66(1):41–7. https://doi.org/10.1111/jgs.15041.CrossRefPubMed

Bostwick D, Wolf St, Samsa G, et al. Comparing the palliative care needs of those with cancer to those with common non-cancer serious illness. J Pain Symptom Manage. 2017;53(6):1079–1084.e1.CrossRef

Köstenberger M, Neuwersch S, Weixler D, Pipam W, Zink M, Likar R. Prevalence of palliative care patients in emergency departments. Wien Klin Wochenschr. 2019;131(17–18):404–9. https://doi.org/10.1007/s00508-019-1530-5.CrossRefPubMed

World Health Organization. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. CC BY-NC-SA 3.0 IGO. Geneva: WHO; 2018.

Anekar AA, Cascella M. WHO analgesic ladder. 2020. https://www.ncbi.nlm.nih.gov/books/NBK554435/. Accessed 17 May 2020.

https://www.basg.gv.at/fileadmin/redakteure/06_Gesundheitsberufe/DHPC/2013/131028_Diclofenac-1.pdf. Accessed 24 Jan 2021.

European Medicines Agency. PRAC recommends the samecardiovascular precautions for diclofenac as for selective COX‑2 inhibitors. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144451.pdf. Accessed 24 Jan 2021.

European Medicines Agency. New safety advice for diclofenac. New measures aim to minimise cardiovascular risks. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diclofenaccontaining_medicinal_products/European_Commission_final_decision/WC500155819.pdf. Accessed 24 Jan 2021.

10.

European Medicines Agency. PRAC recommends updating advice on use of high-dose ibuprofen. Review confirms small increased cardiovascular risk with daily doses at or above 2,400 mg. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500185426.pdf. Accessed 24 Jan 2021.

11.

Reinecke H, Sorgatz H. S3 guideline LONTS. Long-term administration of opioids for non-tumor pain. Schmerz. 2009;23(5):440–7. https://doi.org/10.1007/s00482-009-0839-9.CrossRefPubMed

12.

Heiskanen T, Mätzke S, Haakana S, Gergov M, Vuori E, Kalso E. Transdermal fentanyl in cachectic cancer patients. Pain. 2009;144(1–2):218–22. https://doi.org/10.1016/j.pain.2009.04.012.CrossRefPubMed

13.

Chiba T, Takahashi H, Tairabune T, Kimura S, Ueda H, Kudo K. Cancer cachexia may hinder pain control when using fentanyl patch. Biol Pharm Bull. 2020;43(5):873–8. https://doi.org/10.1248/bpb.b19-01086.CrossRefPubMed

14.

Sittl R, Likar R, Nautrup PB. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther. 2005;27(2):225–37.CrossRef

15.

Wilcock A, Charlesworth S, Toller CS, Girish R, Mihalyo M, Howard P. Denosumab: AHFS 92:24. J Pain Symptom Manage. 2018;56(2):295–301. https://doi.org/10.1016/j.jpainsymman.2018.05.021.CrossRefPubMed

16.

Porta-Sales J, Garzón-Rodríguez C, Llorens-Torromé S, Brunelli C, Pigni A, Caraceni A. Evidence on the analgesic role of bisphosphonates and denosumab in the treatment of pain due to bone metastases: a systematic review within the European Association for Palliative Care guidelines project. Palliat Med. 2017;31(1):5–25. https://doi.org/10.1177/0269216316639793.CrossRefPubMed

17.

Rasche T, Emmert D, Radbruch L, et al. Cannabis und Cannabinoide in der Palliativversorgung. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2019;62:830–5. https://doi.org/10.1007/s00103-019-02967-1.CrossRefPubMed

Titel: Pain and palliative care treatment in daily practice
verfasst von: Dr. Markus Köstenberger
Univ.-Prof. Dr. Rudolf Likar, MSc
Publikationsdatum: 26.01.2021
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 1/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-021-00685-6

Sarcopenia in cancer—a focus on elderly cancer patients

Open Access
short review

Immunoglobulin light chain amyloidosis

Open Access
short review

Monoclonal gammopathy of renal significance

Open Access
short review

Best of ASCO 2020

editorial

Chemotherapy-induced peripheral neuropathy (CIPN)

short review

Paraprotein-associated diseases: a complex relationship between monoclonal gammopathy of unknown significance and severe organ damage

editorial

Springer Medizin Österreich

Pain and palliative care treatment in daily practice

Summary

Weitere Artikel der Ausgabe 1/2021

Sarcopenia in cancer—a focus on elderly cancer patients

Immunoglobulin light chain amyloidosis

Monoclonal gammopathy of renal significance

Best of ASCO 2020

Chemotherapy-induced peripheral neuropathy (CIPN)

Paraprotein-associated diseases: a complex relationship between monoclonal gammopathy of unknown significance and severe organ damage

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Sarcopenia in cancer—a focus on elderly cancer patients

Immunoglobulin light chain amyloidosis

Monoclonal gammopathy of renal significance

Best of ASCO 2020

Chemotherapy-induced peripheral neuropathy (CIPN)

Paraprotein-associated diseases: a complex relationship between monoclonal gammopathy of unknown significance and severe organ damage